Abstract
Extensive studies have evaluated the risks, benefits, and indications for progestins and estrogens, but androgens have received minimal attention. Currently, physicians prescribe testosterone as replacement therapy for hypogonadism, and athletes often receive pharmacological amounts of androgens without medical supervision. Androgen use is prevalent and likely to increase. Concerns about the risks and benefits of androgen therapy thus led to a workshop conference on current knowledge and to target key areas for future study. This workshop conference was attended by over 180 experts in the field. This report summarizes the consensus that was developed.1 The conference was sponsored by the Contraceptive Research and Development Program of the Eastern Virginia Medical School (Norfolk, VA), the Special Progamme of Research Development and Research Training in Human Reproduction of the World Health Organization, the U.S. Food and Drug Administration, and the National Institute of Child Health and Human Develop...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
